Efficacy and Safety of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Non-BRCA Mutation Subgroup of Patients with Metastatic Castration-resistant Prostate Cancer in the PROpel Trial

Niven Mehra, Noel W. Clarke, Andrew J. Armstrong, Mototsugu Oya, Neal Shore, Giuseppe Procopio, João Daniel Guedes, Cagatay Arslan, Emma Brown, Jae Young Joung, Mikio Sugimoto, Young Deuk Choi, Daniel Castellano, Yüksel Ürün, Christian Hosius, David McGuinness, Arnold Degboe, Fred Saad

Open source

DOI: 10.1016/j.euo.2026.08.014
Published: 2026-10
Container: European Urology Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.euo.2026.08.014,
  title = {Efficacy and Safety of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Non-BRCA Mutation Subgroup of Patients with Metastatic Castration-resistant Prostate Cancer in the PROpel Trial},
  author = {Niven Mehra and Noel W. Clarke and Andrew J. Armstrong and Mototsugu Oya and Neal Shore and Giuseppe Procopio and João Daniel Guedes and Cagatay Arslan and Emma Brown and Jae Young Joung and Mikio Sugimoto and Young Deuk Choi and Daniel Castellano and Yüksel Ürün and Christian Hosius and David McGuinness and Arnold Degboe and Fred Saad},
  year = {2026},
  journal = {European Urology Oncology},
  doi = {10.1016/j.euo.2026.08.014},
  url = {https://doi.org/10.1016/j.euo.2026.08.014}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Non-BRCA Mutation Subgroup of Patients with Metastatic Castration-resistant Prostate Cancer in the PROpel Trial
AU  - Niven Mehra
AU  - Noel W. Clarke
AU  - Andrew J. Armstrong
AU  - Mototsugu Oya
AU  - Neal Shore
AU  - Giuseppe Procopio
AU  - João Daniel Guedes
AU  - Cagatay Arslan
AU  - Emma Brown
AU  - Jae Young Joung
AU  - Mikio Sugimoto
AU  - Young Deuk Choi
AU  - Daniel Castellano
AU  - Yüksel Ürün
AU  - Christian Hosius
AU  - David McGuinness
AU  - Arnold Degboe
AU  - Fred Saad
PY  - 2026
JO  - European Urology Oncology
DO  - 10.1016/j.euo.2026.08.014
UR  - https://doi.org/10.1016/j.euo.2026.08.014
ER  -

APA

Mehra, N., Clarke, N. W., Armstrong, A. J., Oya, M., Shore, N., Procopio, G., Guedes, J. D., Arslan, C., Brown, E., Joung, J. Y., Sugimoto, M., Choi, Y. D., Castellano, D., Ürün, Y., Hosius, C., McGuinness, D., Degboe, A., & Saad, F. (2026). Efficacy and Safety of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Non-BRCA Mutation Subgroup of Patients with Metastatic Castration-resistant Prostate Cancer in the PROpel Trial. European Urology Oncology. https://doi.org/10.1016/j.euo.2026.08.014

Source records

crossref · retrieved 2026-11-08T21:04:37.436Z